Cargando…

Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent

BACKGROUND: The World Health Organization (WHO) announced the COVID-19 occurrence as a global pandemic in March 2020. The treatment of SARS-CoV-2 patients is based on the experience gained from SARS-CoV and MERS-CoV infection during 2003. There is no clinically accepted therapeutic drug(s) accessibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Vijay K., Shirbhate, Ekta, Patel, Preeti, Veerasamy, Ravichandran, Sharma, Prabodh C., Rajak, Harish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567120/
https://www.ncbi.nlm.nih.gov/pubmed/34751250
http://dx.doi.org/10.1186/s43088-021-00165-0
_version_ 1784594167122362368
author Patel, Vijay K.
Shirbhate, Ekta
Patel, Preeti
Veerasamy, Ravichandran
Sharma, Prabodh C.
Rajak, Harish
author_facet Patel, Vijay K.
Shirbhate, Ekta
Patel, Preeti
Veerasamy, Ravichandran
Sharma, Prabodh C.
Rajak, Harish
author_sort Patel, Vijay K.
collection PubMed
description BACKGROUND: The World Health Organization (WHO) announced the COVID-19 occurrence as a global pandemic in March 2020. The treatment of SARS-CoV-2 patients is based on the experience gained from SARS-CoV and MERS-CoV infection during 2003. There is no clinically accepted therapeutic drug(s) accessible yet for the treatment of COVID-19. MAIN BODY: Corticosteroids, i.e., dexamethasone, methylprednisolone, hydrocortisone and prednisone are used alone or in combination for the treatment of moderate, severe and critically infected COVID-19 patients who are hospitalized and require supplemental oxygen as per current management strategies and guidelines for COVID-19 published by the National Institutes of Health. Corticosteroids are recorded in the WHO model list of essential medicines and are easily accessible worldwide at a cheaper cost in multiple formulations and various dosage forms. Corticosteroid can be used in all age group of patients, i.e., children, adult, elderly and during pregnancy or breastfeeding women. Corticosteroids have potent anti-inflammatory and immunosuppressive effects in both primary and secondary immune cells, thereby reducing the generation of proinflammatory cytokines and chemokines and lowering the activation of T cells, monocytes and macrophages. The corticosteroids should not be used in the treatment of non-severe COVID-19 patients because corticosteroids suppress the immune response and reduce the symptoms and associated side effects such as slow recovery, bacterial infections, hypokalemia, mucormycosis and finally increase the chances of death. CONCLUSION: Intensive research on corticosteroid therapy in COVID-19 treatment is urgently needed to elucidate their mechanisms and importance in contributing toward successful prevention and treatment approaches. Hence, this review emphasizes on recent advancement on corticosteroid therapy for defining their importance in overcoming SARS-CoV-2 pandemic, their mechanism, efficacy and extent of corticosteroids in the treatment of COVID-19 patients.
format Online
Article
Text
id pubmed-8567120
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-85671202021-11-04 Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent Patel, Vijay K. Shirbhate, Ekta Patel, Preeti Veerasamy, Ravichandran Sharma, Prabodh C. Rajak, Harish Beni Suef Univ J Basic Appl Sci Review BACKGROUND: The World Health Organization (WHO) announced the COVID-19 occurrence as a global pandemic in March 2020. The treatment of SARS-CoV-2 patients is based on the experience gained from SARS-CoV and MERS-CoV infection during 2003. There is no clinically accepted therapeutic drug(s) accessible yet for the treatment of COVID-19. MAIN BODY: Corticosteroids, i.e., dexamethasone, methylprednisolone, hydrocortisone and prednisone are used alone or in combination for the treatment of moderate, severe and critically infected COVID-19 patients who are hospitalized and require supplemental oxygen as per current management strategies and guidelines for COVID-19 published by the National Institutes of Health. Corticosteroids are recorded in the WHO model list of essential medicines and are easily accessible worldwide at a cheaper cost in multiple formulations and various dosage forms. Corticosteroid can be used in all age group of patients, i.e., children, adult, elderly and during pregnancy or breastfeeding women. Corticosteroids have potent anti-inflammatory and immunosuppressive effects in both primary and secondary immune cells, thereby reducing the generation of proinflammatory cytokines and chemokines and lowering the activation of T cells, monocytes and macrophages. The corticosteroids should not be used in the treatment of non-severe COVID-19 patients because corticosteroids suppress the immune response and reduce the symptoms and associated side effects such as slow recovery, bacterial infections, hypokalemia, mucormycosis and finally increase the chances of death. CONCLUSION: Intensive research on corticosteroid therapy in COVID-19 treatment is urgently needed to elucidate their mechanisms and importance in contributing toward successful prevention and treatment approaches. Hence, this review emphasizes on recent advancement on corticosteroid therapy for defining their importance in overcoming SARS-CoV-2 pandemic, their mechanism, efficacy and extent of corticosteroids in the treatment of COVID-19 patients. Springer Berlin Heidelberg 2021-11-04 2021 /pmc/articles/PMC8567120/ /pubmed/34751250 http://dx.doi.org/10.1186/s43088-021-00165-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Patel, Vijay K.
Shirbhate, Ekta
Patel, Preeti
Veerasamy, Ravichandran
Sharma, Prabodh C.
Rajak, Harish
Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent
title Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent
title_full Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent
title_fullStr Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent
title_full_unstemmed Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent
title_short Corticosteroids for treatment of COVID-19: effect, evidence, expectation and extent
title_sort corticosteroids for treatment of covid-19: effect, evidence, expectation and extent
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567120/
https://www.ncbi.nlm.nih.gov/pubmed/34751250
http://dx.doi.org/10.1186/s43088-021-00165-0
work_keys_str_mv AT patelvijayk corticosteroidsfortreatmentofcovid19effectevidenceexpectationandextent
AT shirbhateekta corticosteroidsfortreatmentofcovid19effectevidenceexpectationandextent
AT patelpreeti corticosteroidsfortreatmentofcovid19effectevidenceexpectationandextent
AT veerasamyravichandran corticosteroidsfortreatmentofcovid19effectevidenceexpectationandextent
AT sharmaprabodhc corticosteroidsfortreatmentofcovid19effectevidenceexpectationandextent
AT rajakharish corticosteroidsfortreatmentofcovid19effectevidenceexpectationandextent